Similar articles

• Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.

  [No authors listed] [No authors listed] Semin Urol. 1990 Aug;8(3):159-65. Semin Urol. 1990. PMID: 2204980 Clinical Trial. No abstract available.
• Total androgen ablation: American experience.

  Crawford ED, Nabors WL. Crawford ED, et al. Urol Clin North Am. 1991 Feb;18(1):55-63. Urol Clin North Am. 1991. PMID: 1899495
• [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].

  Knönagel H, Bolle JF, Hering F, Senn E, Hodel T, Neuenschwander H, Biedermann C. Knönagel H, et al. Helv Chir Acta. 1989 Aug;56(3):343-5. Helv Chir Acta. 1989. PMID: 2681086 Clinical Trial. German.
• [Complete androgen blockage in the treatment of metastatic prostate cancer].

  Matzkin H, Braf Z. Matzkin H, et al. Harefuah. 1994 Mar 1;126(5):260-3. Harefuah. 1994. PMID: 8188104 Review. Hebrew. No abstract available.
• Prostatic cancer--what to do? Staging and prognostic factors in the primary therapy decision.

  Faul P. Faul P. Eur Urol. 1992;22(2):89-98. Eur Urol. 1992. PMID: 1478236 Review. No abstract available.